Ionis shares plunge $1B after cutting sales forecast for triglyceride drug

Ionis Pharmaceuticals cut sales projections for its triglyceride-lowering drug, triggering a $1 billion market value loss. The slow rollout signals weaker-than-expected commercial uptake, raising uncertainty about near-term revenue and growth outlook.

AI disclosure: Model-written summary of the source, not a verified fact. Check the sources. How Mosaic works